REFERENCES
1. Grigoriu B, Berghmans T, Meert AP. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur Respir J 2015;45:1132-41.
2. Boehrer S, Adès L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008;111:2170-80.
3. Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017;7:818-31.
4. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008;111:4788-96.
5. Sun JZ, Lu Y, Xu Y, et al. Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis. Hematol Oncol 2012;30:89-97.
6. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005;106:2841-8.
7. Boehrer S, Adès L, Galluzzi L, et al. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochem Pharmacol 2008;76:1417-25.
8. Lindhagen E, Eriksson A, Wickström M, et al. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 2008;81:344-53.
9. Onetto-Pothier N, Aumont N, Haman A et al. IL-3 inhibits the binding of GM-CSF to AML blasts, but the two cytokines act synergistically in supporting blast proliferation. Leukemia 1990;4:329-36.
10. Nievergall E, Ramshaw HS, Yong AS, et al. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014;123:1218-28.
11. Radpour R, Riether C, Simillion C, Höpner S, Bruggmann R, Ochsenbein AF. CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. Leukemia 2019;33:2379-92.
12. Mahmud H, Kornblau SM, Ter Elst A, et al. Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. J Hematol Oncol 2016;9:64.
13. Miranda MB, Duan R, Thomas SM, et al. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia 2008;22:1624-7.
14. Noh EK, Kim H, Park MJ, et al. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. Leuk Res 2010;34:1501-5.
15. Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009;16:281-94.
16. Cao ZX, Guo CJ, Song X, et al. Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. FASEB J 2020;34:10182-90.
17. Boehrer S, Galluzzi L, Lainey E, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 2011;10:3168-75.
18. Deangelo DJ, Neuberg D, Amrein PC, et al. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res 2014;38:430-4.
19. Abou Dalle I, Cortes JE, Pinnamaneni P, et al. A pilot phase II study of erlotinib for the treatment of patients with relapsed/refractory acute myeloid leukemia. Acta Haematol 2018;140:30-9.
20. Sayar H, Czader M, Amin C, Cangany M, Konig H, Cripe LD. Pilot study of erlotinib in patients with acute myeloid leukemia. Leuk Res 2015;39:170-2.
21. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6.
22. Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005;117:883-8.
23. Russo A, Franchina T, Ricciardi GR, et al. Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer. Oncotarget 2017;8:8717-25.
24. Jorissen R. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
25. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
26. Rayego-Mateos S, Rodrigues-Díez R, Morgado-Pascual JL, et al. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J Mol Cell Biol 2013;5:323-35.
27. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. Molecular determinants of epidermal growth factor binding: a molecular dynamics study. PLoS One 2013;8:e54136.
28. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Letters 1999;447:227-31.
29. Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev 2016;96:1025-69.
30. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int 2013;2013:546318.
31. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20:851-5.
32. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-506.
33. Nath S, Bhattacharyya J, Sarma PP, et al. The prognostic impact of epidermal growth factor receptor (EGFR) in patients with acute myeloid leukaemia. Indian J Hematol Blood Transfus 2020;36:749-53.
34. Nath S, Bhattacharyya J, Chandra P, Saxena R, Sazawal S, Saikia KK. Clinicopathological significance of common genetic alterations in patients with acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther 2020;S1658-3876(20)30121.
35. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007;110:1079-80.
36. Ryan MA, Nattamai KJ, Xing E, et al. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 2010;16:1141-6.
37. Löwenberg B, van Putten W, Theobald M, et al. Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52.
38. Konuma T, Ooi J, Uchida N, et al. Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica 2014;99:e264-8.
39. Haouas H, Haouas S, Uzan G, Hafsia A. Identification of new markers discriminating between myeloid and lymphoid acute leukemia. Hematology 2010;15:193-203.
40. Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood 1999;93:1715-23.
41. Mussai F, Egan S, Higginbotham-Jones J, et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 2015;125:2386-96.
42. Riese DJ 2nd, Cullum RL. Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 2014;28:49-56.
43. Wu X, Qureshi IA, Liu H, Yin J, Qian X, Ruijie X. Epidermal growth factor in acute promyelocytic leukemia treated with retinoic acid. Int J Hemato ;62:83-9.
44. Callegari C, Laborde NP, Buenaflor G, Nascimento CG, Brasel JA, Fisher DA. The source of urinary epidermal growth factor in humans. Eur J Appl Physiol Occup Physiol 1988;58:26-31.
45. Ramadan A, Griesenauer B, Adom D, et al. Specifically differentiated T cell subset promotes tumor immunity over fatal immunity. J Exp Med 2017;214:3577-96.
46. Corrado C, Saieva L, Raimondo S, Santoro A, De Leo G, Alessandro R. Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor. J Cell Mol Med 2016;20:1829-39.
47. Doan PL, Himburg HA, Helms K, et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med 2013;19:295-304.
48. Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143.
49. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 2013;34:8690-707.
50. Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2004;6 Suppl 1:S7-S19.
51. Huang J, Meng L, Yang B, Sun S, Luo Z, Chen H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system. Sci Rep 2020;10:4803.
52. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008;26:3645-6.
53. Boros K, Puissant A, Back M, et al. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget 2015;6:25575-87.
54. Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 2014;25:226-42.
55. Lainey E, Wolfromm A, Marie N, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2013;32:4331-42.
56. Lainey E, Wolfromm A, Sukkurwala AQ, et al. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. Cell Cycle 2013;12:2978-91.
57. Lainey E, Sébert M, Thépot S, et al. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012;11:4079-92.
